On 25 April 2023, the drug tofersen, an antisense oligonucleotide, received the US Food and Drug Administration approval for treating ALS in adults carrying mutations of the SOD1 gene. The gene discussed is SOD1; the disease is amyotrophic lateral sclerosis.